Human papillomavirus types by age in cervical cancer precursors: Predominance of human papillomavirus 16 in young women

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 3, 2009, Pages 863-865

  Porras, Carolina ^a   Rodríguez, Ana Cecilia ^a   Hildesheim, Allan ^b   Herrero, Rolando ^a   González, Paula ^a   Wacholder, Sholom ^b   Burk, Robert D ^c   Schiffman, Mark ^b  

^a PROYECTO EPIDEMIOLÓGICO GUANACASTE   (Costa Rica)

^b NATIONAL CANCER INSTITUTE   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGEN;

ADULT; AGE DISTRIBUTION; ARTICLE; CONTROLLED STUDY; COSTA RICA; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INCIDENCE; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VERRUCA VULGARIS; WART VIRUS; ADOLESCENT; AGE; CHI SQUARE DISTRIBUTION; ISOLATION AND PURIFICATION; MIDDLE AGED; PATHOGENICITY; VIROLOGY; VIRUS INFECTION;

ADOLESCENT; ADULT; AGE FACTORS; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHI-SQUARE DISTRIBUTION; COSTA RICA; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; TUMOR VIRUS INFECTIONS;

EID: 64549086045     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0951     Document Type: Article

References (21)

1. Muñoz N, Bosch FX, de Sanjosé S, et al.; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-527
2. Cogliano V, Baan R, Straif K, et al.; WHO International Agency for Research on Cancer. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005;6:204.
3. Kjaer S, Høgdall E, Frederiksen K, et al. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res 2006;66:10630-10636 (Pubitemid 44799787)
4. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005;97:1072-1079 (Pubitemid 41417924)
5. Castle PE, Solomon D, Schiffman M, et al. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst 2005;97:1066-1071 (Pubitemid 41417923)
6. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007;121:621-632 (Pubitemid 46986496)
7. Clifford G, Franceschi S, Diaz M, et al. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 2006;24 Suppl 3:S26-34. (Pubitemid 44293021)
8. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007;356:1944-1956 (Pubitemid 46740304)
9. Herrero R, Castellsagué X, Pawlita M, et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst 2003;95:1772-1783 (Pubitemid 38008900)
10. Bulk S, Berkhof J, Bulkmans NW, et al. Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands. Br J Cancer 2006;94:171-175 (Pubitemid 43088560)
11. Zielinski GD, Snijders PJ, Rozendaal L, et al. The presence of highrisk HPV combined with specific p53 and p16INK4a expression patterns points to high-risk HPV as the main causative agent for adenocarcinoma in situ and adenocarcinoma of the cervix. J Pathol 2003;201:535-543 (Pubitemid 38256402)
12. Herrero R, Schiffman MH, Bratti C, et al. Design and methods of a population-based natural history study of cervical neoplasia in a rural province of Costa Rica: the Guanacaste Project. Rev Panam Salud Publica 1997;1:362-375 (Pubitemid 27428425)
13. Bratti MC, Rodríguez AC, Schiffman M, et al. Description of a seven-year prospective study of human papillomavirus infection and cervical neoplasia among 10000 women in Guanacaste, Costa Rica,. Rev Panam Salud Publica 2004;15:75-89. (Pubitemid 38402500)
14. Herrero R, Castle PE, Schiffman M, et al. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis 2005;191:1796-1807 (Pubitemid 40705385)
15. Vinokurova S, Wentzensen N, Kraus I, et al. Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res 2008;68:307-313
16. Rodríguez AC, Schiffman M, Herrero R, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 2008;100:513-517
17. Winer RL, Kiviat NB, Hughes JP, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 2005;191:731-738 (Pubitemid 40271061)
18. Strickler HD, Palefsky JM, Shah KV, et al. Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. J Natl Cancer Inst 2003;95:1062-1071 (Pubitemid 36950110)
19. Herrero R, Hildesheim A, Rodríguez AC, et al. Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. Vaccine 2008;26:4795-4808
20. Kovacic MB, Castle PE, Herrero R, et al. Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality. Cancer Res 2006;66:10112-10119 (Pubitemid 44672065)
21. Massad LS, Jeronimo J, Schiffman M, et al. Interobserver agreement in the assessment of components of colposcopic grading. Obstet Gynecol 2008;111:1279-1284